Clinical and immunological characteristics of the study cohort
| Label | Course of infection | Peak ALT | Age, sex | Therapy | Therapy outcome | Genoytpe | Risk factor | First sample | No of CD4+ responses | First sample VL | Peak VL | Nadir VL |
| d | IU/ml | IU/ml | IU/ml | |||||||||
| AC1 | AC | 473 | 35, M | None | Chronic | 1 | IDU | 94 | 2 | 42,000 | 42,000 | 42,000 |
| AC2 | AC | 2915 | 20, F | PEG/RBV 24W | SVR | 1a | IDU | 125 | 1 | 358,000 | >700,000 | 235,000 |
| AC3 | AC | 206 | 19, F | PEG/RBV 24W | SVR | 1b | IDU | 49 | 13 | 2800 | 358,000 | 1080 |
| AC4 | AC | 201 | 30, M | PEG/RBV 48W | SVR | 1a | IDU | 107 | 1 | 7470 | 7470 | 7470 |
| AC5 | AC | 720 | 28, M | IFN 6 mIU tiw 48W | Relapse | 1 | Hospitalization | 137 | 3 | >700,000 | >700,000 | 194,000 |
| AC6 | AC | 420 | 26, M | PEG 24W | SVR | 1a | IDU | 100 | 1 | 234,000 | 234,000 | 120,647 |
| AC7 | AC | 1074 | 37, M | PEG/RBV 24W | SVR | 1b | IDU | 0 | 13 | >700,000 | >700,000 | +* |
| AC8 | AC | 2145 | 23, F | PEG/RBV 12W | SVR | 1 | IDU | 35 | 17 | 902 | 902 | +* |
| AC9 | AC | 678 | 38, M | None | Chronic | 1 | IDU | 62 | 6 | 380,000 | 380,000 | 380,000 |
| AC10 | AC | 308 | 20, F | PEG/RBV 24W | SVR | 1b | IDU | 53 | 12 | >700,000 | >700,000 | 342 |
| AC11 | AC | 427 | 40, F | IFN 3 mIU tiw/RBV | SVR | 1a | Needle Stick | 14 | 12 | 900 | >700,000 | 900 |
| AC12 | AC | 1074 | 37, M | None | Chronic | 1a | IDU | 54 | 6 | >700,000 | >700,000 | 456,999 |
| AC13 | AC | 1204 | 55, F | PEG/RBV 24W | SVR | 2** | Needle stick | 7 | 13 | >700,000 | >700,000 | +* |
| AR1 | AR | 2237 | 27, M | NA | NA | 3** | IDU | 16 | 7 | +* | +* | NA |
| AR2 | AR | 331 | 33, M | NA | NA | NA | Cocaine | 41 | 2 | +* | +* | NA |
| AR3 | AR | 1630 | 28, F | NA | NA | 1** | IDU | 30 | 22 | 7215 | 7215 | NA |
| AR4 | AR | 1673 | 21, F | NA | NA | 1a | IDU | 7 | 20 | >700,000 | >700,000 | NA |
| AR5 | AR | 443 | 41, F | NA | NA | 1** | Blood Transfusion | 56 | 26 | 260,830 | 260,830 | NA |
| AR6 | AR | 1845 | 38, F | NA | NA | 1** | Surgery | 156 | 12 | +* | +* | NA |
| AR7 | AR | 1235 | 31, M | NA | NA | 1** | Surgery | 27 | 17 | +* | +* | NA |
| AR8 | AR | 1073 | 42, M | NA | NA | 1** | IDU | 20 | 5 | 55,700 | 55,700 | NA |
| AR9 | AR | 918 | 35, F | NA | NA | 1** | Hospitalization | 26 | 14 | 4000 | 4000 | NA |
| AR10 | AR | 463 | 29, M | NA | NA | 3a | IDU | 15 | 8 | 211,195 | 211,195 | NA |
| AR11 | AR | 1327 | 47, F | NA | NA | 1** | Sexual Transmission | 112 | 16 | +* | +* | NA |
| AR12 | AR | 2235 | 31, F | NA | NA | 1** | Hospitalization | 44 | 5 | 9700 | 9700 | NA |
| AR13 | AR | 1694 | 59, F | NA | NA | 1** | Hospitalization | 18 | 11 | 342000 | 342000 | NA |
| AR14 | AR | 2659 | 39, F | NA | NA | 1a | IDU | 12 | 9 | 734,400 | 734,400 | NA |
| AR15 | AR | 201 | 23, F | NA | NA | 1a | IDU/Cocaine | 14 | 5 | 3200 | 3200 | NA |
| AR16 | AR | 1624 | 22, F | NA | NA | 1** | IDU | 108 | 17 | +* | +* | NA |
| AR17 | AR | 2435 | 63, F | NA | NA | 1** | Unknown | 177 | 9 | +* | +* | NA |
| AR18 | AR | 1060 | 52, F | NA | NA | NA | Sexual Transmission | 57 | 5 | +* | +* | NA |
| Label | Course of infection | Peak ALT | Age, sex | Therapy | Therapy outcome | Genoytpe | Risk factor | First sample | No of CD4+ responses | First sample VL | Peak VL | Nadir VL |
| d | IU/ml | IU/ml | IU/ml | |||||||||
| AC1 | AC | 473 | 35, M | None | Chronic | 1 | IDU | 94 | 2 | 42,000 | 42,000 | 42,000 |
| AC2 | AC | 2915 | 20, F | PEG/RBV 24W | SVR | 1a | IDU | 125 | 1 | 358,000 | >700,000 | 235,000 |
| AC3 | AC | 206 | 19, F | PEG/RBV 24W | SVR | 1b | IDU | 49 | 13 | 2800 | 358,000 | 1080 |
| AC4 | AC | 201 | 30, M | PEG/RBV 48W | SVR | 1a | IDU | 107 | 1 | 7470 | 7470 | 7470 |
| AC5 | AC | 720 | 28, M | IFN 6 mIU tiw 48W | Relapse | 1 | Hospitalization | 137 | 3 | >700,000 | >700,000 | 194,000 |
| AC6 | AC | 420 | 26, M | PEG 24W | SVR | 1a | IDU | 100 | 1 | 234,000 | 234,000 | 120,647 |
| AC7 | AC | 1074 | 37, M | PEG/RBV 24W | SVR | 1b | IDU | 0 | 13 | >700,000 | >700,000 | +* |
| AC8 | AC | 2145 | 23, F | PEG/RBV 12W | SVR | 1 | IDU | 35 | 17 | 902 | 902 | +* |
| AC9 | AC | 678 | 38, M | None | Chronic | 1 | IDU | 62 | 6 | 380,000 | 380,000 | 380,000 |
| AC10 | AC | 308 | 20, F | PEG/RBV 24W | SVR | 1b | IDU | 53 | 12 | >700,000 | >700,000 | 342 |
| AC11 | AC | 427 | 40, F | IFN 3 mIU tiw/RBV | SVR | 1a | Needle Stick | 14 | 12 | 900 | >700,000 | 900 |
| AC12 | AC | 1074 | 37, M | None | Chronic | 1a | IDU | 54 | 6 | >700,000 | >700,000 | 456,999 |
| AC13 | AC | 1204 | 55, F | PEG/RBV 24W | SVR | 2** | Needle stick | 7 | 13 | >700,000 | >700,000 | +* |
| AR1 | AR | 2237 | 27, M | NA | NA | 3** | IDU | 16 | 7 | +* | +* | NA |
| AR2 | AR | 331 | 33, M | NA | NA | NA | Cocaine | 41 | 2 | +* | +* | NA |
| AR3 | AR | 1630 | 28, F | NA | NA | 1** | IDU | 30 | 22 | 7215 | 7215 | NA |
| AR4 | AR | 1673 | 21, F | NA | NA | 1a | IDU | 7 | 20 | >700,000 | >700,000 | NA |
| AR5 | AR | 443 | 41, F | NA | NA | 1** | Blood Transfusion | 56 | 26 | 260,830 | 260,830 | NA |
| AR6 | AR | 1845 | 38, F | NA | NA | 1** | Surgery | 156 | 12 | +* | +* | NA |
| AR7 | AR | 1235 | 31, M | NA | NA | 1** | Surgery | 27 | 17 | +* | +* | NA |
| AR8 | AR | 1073 | 42, M | NA | NA | 1** | IDU | 20 | 5 | 55,700 | 55,700 | NA |
| AR9 | AR | 918 | 35, F | NA | NA | 1** | Hospitalization | 26 | 14 | 4000 | 4000 | NA |
| AR10 | AR | 463 | 29, M | NA | NA | 3a | IDU | 15 | 8 | 211,195 | 211,195 | NA |
| AR11 | AR | 1327 | 47, F | NA | NA | 1** | Sexual Transmission | 112 | 16 | +* | +* | NA |
| AR12 | AR | 2235 | 31, F | NA | NA | 1** | Hospitalization | 44 | 5 | 9700 | 9700 | NA |
| AR13 | AR | 1694 | 59, F | NA | NA | 1** | Hospitalization | 18 | 11 | 342000 | 342000 | NA |
| AR14 | AR | 2659 | 39, F | NA | NA | 1a | IDU | 12 | 9 | 734,400 | 734,400 | NA |
| AR15 | AR | 201 | 23, F | NA | NA | 1a | IDU/Cocaine | 14 | 5 | 3200 | 3200 | NA |
| AR16 | AR | 1624 | 22, F | NA | NA | 1** | IDU | 108 | 17 | +* | +* | NA |
| AR17 | AR | 2435 | 63, F | NA | NA | 1** | Unknown | 177 | 9 | +* | +* | NA |
| AR18 | AR | 1060 | 52, F | NA | NA | NA | Sexual Transmission | 57 | 5 | +* | +* | NA |
AC patient was recruited and studied within 6 mo after onset of symptoms and remained viremic after 6 mo; AR patient was recruited and studied within 6 mo after onset of symptoms, and tested HCV RNA negative on at least two occasions after 6 mo and later; ALT, alanine transaminase; M, male; F, female; PEG, pegylated interferon α; RBV, Ribavirin; tiw, three times weekly; IU, international units; IDU, intravenous drug use; VL, viral load, NA, not applicable. *, + HCV PCR, too low to quantify. **, serotype.